Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000210619 | SCV000262909 | pathogenic | Inborn genetic diseases | 2014-03-31 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000668646 | SCV000793280 | likely pathogenic | Cohen syndrome | 2017-10-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000668646 | SCV001586271 | pathogenic | Cohen syndrome | 2023-08-17 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln3183*) in the VPS13B gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in VPS13B are known to be pathogenic (PMID: 15141358, 16648375, 20461111). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with VPS13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 225027). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |